NLS Pharmaceutics Ltd
NLSP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.15M
Close$
$1.08
62.9% downside
Current Fair Value
62.9% downsideOvervalued by 62.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.15 Million |
|---|---|
| Enterprise Value | $829,500.00 |
| Earnings per Share | $-26.3 |
| Beta | 0.13 |
| Outstanding Shares | 400,487 |
Return
| Return on Equity | -11.92% |
|---|---|
| Return on Assets | -7.42% |
| Return on Invested Capital | -126.77% |
Valuation & Multiples
| P/E Ratio | 7.73 |
|---|---|
| PEG | 25.26 |
| Price to Sales | - |
| Price to Book Ratio | 0.19 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.47 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Institutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▲ 0.00% |
|---|---|
| Total Invested | $66▼ 36.54% |
| Investors Holding | 10% |
About NLS Pharmaceutics Ltd
4 employees
CEO: Ronen Twito
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system d...